Importantly, we have shown that the combination of GLP-1 and PYY3–36 retains the glucose-lowering insulinotropic effect observed with GLP-1, which adds further support to the concept of multiple gut hormone therapy as a treatment for diabetes and obesity. The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.